Biopharma: Takeaways from our Investor Dinner with Dianthus Mgt. Team

Research evidence excerpt

Biopharma: Takeaways from our Investor Dinner with Dianthus Mgt. Team

IdeaMSelective C1s targeting may deliver C5-like efficacy with a differentiated safety

profile. Importantly, this efficacy upside is paired with what management views as a

differentiated safety profile. By targeting active C1s rather than broader

complement components, claseprubart avoids shutting down the entire

complement cascade, preserving immune function and reducing risks such as those

associated with C1q inhibition (notably drug-induced lupus) or the infection risk seen

with terminal complement blockade.

Potency is a central pillar of the differentiation narrative. This combination of

mechanism and potency is central to the company’s confidence in the program.

Management repeatedly highlighted data demonstrating a substantial potency

advantage (approximately 7x versus riliprubart and 30–40x versus empasiprubart)

which they view as translating directly into clinical outcomes.

Management now views the program as effectively de-risked based on

competitor data and claseprubart MG and interim CIDP clinical results. This has

led them to characterize the program as “de-risked,” a notable shift in tone that

reflects growing confidence in both the biology and the molecule itself.

CAPTIVATE interim data suggest a potentially step-change in CIDP efficacy. The

CAPTIVATE trial in CIDP remains the key focal point of this thesis. The early GO

decision, triggered after achieving ≥20 responders before completion of the planned

cohort, was described as exceeding internal expectations, with implied response

rates potentially approaching the mid-to-high-70% range based on public disclosures

and investor reconstruction.

Trial design strengthens confidence in the quality and durability of the efficacy

signal.